Glucagon receptor activation stimulates thermogenic and lipolytic signaling pathways
This eat less, feel full effect is a big reason why GLP-1 RAs (such as semaglutide, known by brand names like Ozempic or Wegovy) have become popular for weight management
Relatively early acute changes in appetite, satiety, and prospective food consumption by pharmacological doses of GLP-1 were described, resulting in a corresponding reduction in caloric intake [12], thus increasing the motivation to develop compounds mimicking the physiology of GLP-1 resistant to the proteolytic inactivation by DPP-4 and with slower elimination kinetics to allow for reasonable administration frequencies
Science 305:14661470 Wang Y, Guo D, He J, Song L, Chen H, Zhang Z, Tan N (2019) Inhibition of fatty acid synthesis arrests colorectal neoplasm growth and metastasis: anti-cancer therapeutical effects of natural cyclopeptide RA-XII
In the SUSTAIN-6 study, which compared subcutaneous semaglutide to placebo, DR complications occurred in 3% of semaglutide and 1.8% of placebo subjects
